BioSpace News Archive

Hoag Memorial Hospital Presbyterian welcomed last week’s announcement by the U.S. Food & Drug Administration that the FDA approved the first prostate specific membrane antigen (PSMA)-targeted radiotherapy for metastatic prostate cancer.

Life science researchers can explore new ideas for genome engineering technology through a newly announced post-doctoral research program launched by Promega with mentoring support from AstraZeneca.

Guerbet has recently submitted a New Drug Application to the U.S. Food and Drug Administration and a Centralized Application for Marketing Authorization to the European Medicine Agency for Gadopiclenol, an investigational macrocyclic gadolinium-based contrast agent.

The global Viral Vectors and Plasmid DNA Manufacturing market gathered revenue around USD 2.9 Billion in 2020 and to reach USD 9.0 Billion by 2027 and estimated to expand at a modest CAGR of 19.1% during the prediction period 2021 to 2027.

Researchers have been identifying the different areas in airways and lungs to develop drugs for offering a better quality of life to patients suffering from asthma and chronic obstructive pulmonary disease (COPD).

Tricida, Inc. announced financial results for the three months and year ended December 31, 2021 and provided an update on key initiatives.

Pardes Biosciences, Inc. (NASDAQ: PRDS), today reported financial results for the full year ended December 31, 2021 and provided a business update.

Dyadic International, Inc., a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics announced its financial results for year end 2021 and highlighted recent Company progress.

Texas Biomedical Research Institute has been selected by the National Institutes of Health to host one of the nation’s inaugural training centers for tuberculosis research.

Sera Prognostics Inc., The Pregnancy Company®, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced financial results for the fourth quarter and full year 2021 ended December 31, 2021.